The Monoclonal Anfibody Core provides expert consultafion on antibody development to invesfigators and supports all aspects of anfibody development, including generation of antigens, immunizations, hybridoma fusions, antibody screening, long-term hybridoma storage and small and large-scale anfibody producfion, as well as purificafion and labeling of anfibodies. The Core provides quality antibody reagents and technologies at a reasonable fee so that DF/HCC members can further their research objectives and facilitate their goal to invesfigate, diagnose and treat cancer. This facility was first approved as an Established Shared Resource at the fime ofthe last competitive renewal.
The mission of the Core is to generate novel monoclonal and polyclonal antibodies specific for antigens of interest to Cancer Center investigators. Given the diverse research needs of DF/HCC members, the Core strives to respond to a wide variety of requests for antibody development. Antibodies can be developed for basic and translational research, including the detection of biomarkers indicative of disease status, as well as functional antibodies for therapeutic purposes.
Showing the most recent 10 out of 411 publications